Trial record 2 of 3 for:    iCo-007

A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema (the iDEAL Study)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Juvenile Diabetes Research Foundation
iCo Therapeutics Inc.
Information provided by (Responsible Party):
Quan Dong Nguyen, Johns Hopkins University
ClinicalTrials.gov Identifier:
NCT01565148
First received: March 15, 2012
Last updated: June 24, 2013
Last verified: June 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2013
  Estimated Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)